Navigation path

Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4 methylpiperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide

EU orphan designation number: EU/3/15/1580   
Active ingredient: N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4 methylpiperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide
Indication: Treatment of neuroblastoma
Sponsor: Pharma Gateway AB
Johanneslundsvägen 2, 194 61 Upplands Väsby, Sverige

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page
Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
13/11/2015 Orphan designation EMA/OD/136/15 (2015)8030 of 11/11/2015
13/06/2017 Change of name and/or address of sponsor